BACKGROUND:CER-001 is an engineered pre-beta high-density lipoprotein (HDL) mimetic, which rapidly mobilizes cholesterol. Infusion of CER-001 3 mg/kg exhibited a potentially favorable effect on plaque burden in the CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis Regression) study. Since baseline atheroma burden has been shown as a determinant for the efficacy of HDL infusions, the degree of baseline atheroma burden might influence the effect of CER-001. METHODS: CHI-SQUARE compared the effect of 6 weekly infusions of CER-001 (3, 6 and 12 mg/kg) vs. placebo on coronary atherosclerosis in 369 patients with acute coronary syndrome (ACS) using serial intravascular ultrasound (IVUS). Baseline percent atheroma volume (B-PAV) cutoff associated with atheroma regression following CER-001 infusions was determined by receiver-operating characteristics curve analysis. 369 subjects were stratified according to the cutoff. The effect of CER-001 at different doses was compared to placebo in each group. RESULTS: A B-PAV ≥30% was the optimal cutoff associated with PAV regression following CER-001 infusions. CER-001induced PAV regression in patients with B-PAV ≥30% but not in those with B-PAV <30% (-0.45%±2.65% vs. +0.34%±1.69%, P=0.01). Compared to placebo, the greatest PAV regression was observed with CER-001 3mg/kg in patients with B-PAV ≥30% (-0.96%±0.34% vs. -0.25%±0.31%, P=0.01), whereas there were no differences between placebo (+0.09%±0.36%) versus CER-001 in patients with B-PAV <30% (3 mg/kg; +0.41%±0.32%, P=0.39; 6 mg/kg; +0.27%±0.36%, P=0.76; 12 mg/kg; +0.32%±0.37%, P=0.97). CONCLUSIONS: Infusions of CER-001 3 mg/kg induced the greatest atheroma regression in ACS patients with higher B-PAV. These findings identify ACS patients with more extensive disease as most likely to benefit from HDL mimetic therapy.
RCT Entities:
BACKGROUND:CER-001 is an engineered pre-beta high-density lipoprotein (HDL) mimetic, which rapidly mobilizes cholesterol. Infusion of CER-001 3 mg/kg exhibited a potentially favorable effect on plaque burden in the CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis Regression) study. Since baseline atheroma burden has been shown as a determinant for the efficacy of HDL infusions, the degree of baseline atheroma burden might influence the effect of CER-001. METHODS: CHI-SQUARE compared the effect of 6 weekly infusions of CER-001 (3, 6 and 12 mg/kg) vs. placebo on coronary atherosclerosis in 369 patients with acute coronary syndrome (ACS) using serial intravascular ultrasound (IVUS). Baseline percent atheroma volume (B-PAV) cutoff associated with atheroma regression following CER-001 infusions was determined by receiver-operating characteristics curve analysis. 369 subjects were stratified according to the cutoff. The effect of CER-001 at different doses was compared to placebo in each group. RESULTS: A B-PAV ≥30% was the optimal cutoff associated with PAV regression following CER-001 infusions. CER-001 induced PAV regression in patients with B-PAV ≥30% but not in those with B-PAV <30% (-0.45%±2.65% vs. +0.34%±1.69%, P=0.01). Compared to placebo, the greatest PAV regression was observed with CER-001 3mg/kg in patients with B-PAV ≥30% (-0.96%±0.34% vs. -0.25%±0.31%, P=0.01), whereas there were no differences between placebo (+0.09%±0.36%) versus CER-001 in patients with B-PAV <30% (3 mg/kg; +0.41%±0.32%, P=0.39; 6 mg/kg; +0.27%±0.36%, P=0.76; 12 mg/kg; +0.32%±0.37%, P=0.97). CONCLUSIONS: Infusions of CER-001 3 mg/kg induced the greatest atheroma regression in ACS patients with higher B-PAV. These findings identify ACS patients with more extensive disease as most likely to benefit from HDL mimetic therapy.
Authors: G S Mintz; S E Nissen; W D Anderson; S R Bailey; R Erbel; P J Fitzgerald; F J Pinto; K Rosenfield; R J Siegel; E M Tuzcu; P G Yock Journal: J Am Coll Cardiol Date: 2001-04 Impact factor: 24.094
Authors: Ozgur Bayturan; Samir Kapadia; Stephen J Nicholls; E Murat Tuzcu; Mingyuan Shao; Kiyoko Uno; Ajai Shreevatsa; Andrea J Lavoie; Kathy Wolski; Paul Schoenhagen; Steven E Nissen Journal: J Am Coll Cardiol Date: 2010-06-15 Impact factor: 24.094
Authors: Ruud S Kootte; Loek P Smits; Fleur M van der Valk; Jean-Louis Dasseux; Constance H Keyserling; Ronald Barbaras; John F Paolini; Raul D Santos; Theo H van Dijk; Geesje M Dallinga-van Thie; Aart J Nederveen; Willem J M Mulder; G Kees Hovingh; John J P Kastelein; Albert K Groen; Erik S Stroes Journal: J Lipid Res Date: 2015-01-05 Impact factor: 5.922
Authors: Robert S Rosenson; H Bryan Brewer; W Sean Davidson; Zahi A Fayad; Valentin Fuster; James Goldstein; Marc Hellerstein; Xian-Cheng Jiang; Michael C Phillips; Daniel J Rader; Alan T Remaley; George H Rothblat; Alan R Tall; Laurent Yvan-Charvet Journal: Circulation Date: 2012-04-17 Impact factor: 29.690
Authors: Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; B Greg Brown; Peter Ganz; Robert A Vogel; Tim Crowe; Gail Howard; Christopher J Cooper; Bruce Brodie; Cindy L Grines; Anthony N DeMaria Journal: JAMA Date: 2004-03-03 Impact factor: 56.272
Authors: Rishi Puri; Steven E Nissen; Mingyuan Shao; Christie M Ballantyne; Philip J Barter; M John Chapman; Raimund Erbel; Peter Libby; Joel S Raichlen; Kiyoko Uno; Yu Kataoka; Stephen J Nicholls Journal: Arterioscler Thromb Vasc Biol Date: 2014-09-11 Impact factor: 8.311
Authors: Jean-Claude Tardif; Christie M Ballantyne; Philip Barter; Jean-Louis Dasseux; Zahi A Fayad; Marie-Claude Guertin; John J P Kastelein; Constance Keyserling; Heather Klepp; Wolfgang Koenig; Philippe L L'Allier; Jacques Lespérance; Thomas F Lüscher; John F Paolini; Ahmed Tawakol; David D Waters Journal: Eur Heart J Date: 2014-04-29 Impact factor: 29.983
Authors: Stephen E Henrich; Bong Jin Hong; Jonathan S Rink; SonBinh T Nguyen; C Shad Thaxton Journal: J Am Chem Soc Date: 2019-06-13 Impact factor: 15.419
Authors: Jordan Andrews; Alex Janssan; Tracy Nguyen; Anthony D Pisaniello; Daniel J Scherer; John J P Kastelein; Bela Merkely; Steven E Nissen; Kausik Ray; Gregory G Schwartz; Stephen G Worthley; Connie Keyserling; Jean-Louis Dasseux; Julie Butters; Jacinta Girardi; Rosemary Miller; Stephen J Nicholls Journal: Cardiovasc Diagn Ther Date: 2017-02
Authors: Yu Kataoka; Stephen J Nicholls; Jordan Andrews; Kiyoko Uno; Samir R Kapadia; E Murat Tuzcu; Steven E Nissen; Rishi Puri Journal: Cardiovasc Diagn Ther Date: 2022-02
Authors: Stephen J Nicholls; Jordan Andrews; John J P Kastelein; Bela Merkely; Steven E Nissen; Kausik K Ray; Gregory G Schwartz; Stephen G Worthley; Connie Keyserling; Jean-Louis Dasseux; Liddy Griffith; Susan W Kim; Alex Janssan; Giuseppe Di Giovanni; Anthony D Pisaniello; Daniel J Scherer; Peter J Psaltis; Julie Butters Journal: JAMA Cardiol Date: 2018-09-01 Impact factor: 14.676
Authors: Jun Chen; Xixi Zhang; Reid Millican; Jennifer Sherwood; Sean Martin; Hanjoong Jo; Young-Sup Yoon; Brigitta C Brott; Ho-Wook Jun Journal: Adv Drug Deliv Rev Date: 2021-01-09 Impact factor: 15.470